News
Reinsberg Group acquires majority stake in Brandon Medical
Reinsberg Group, the MedTech holding of BHM Group, has acquired the majority stake in Brandon Medical, a leading UK-based company specialising in the development and manufacturing of medical equipment. This acquisition is a key part of Reinsberg Group’s strategy to build a strong group of independent European medical manufacturers, leveraging their capabilities to achieve economies of scale in the global consolidation of the medical industry. “This move strengthens our market position
especially in the UK market as well as in the area of hospital products, such as lights, integration and other products, while supporting the growth and innovation of Brandon Medical,” said Dr. Markus Keussen, CEO of Reinsberg Group. “We are excited to welcome this company into our family and continue developing it with a focus on its key
products, both in the UK and globally.” Brandon Medical is a renowned UK manufacturer and designer of advanced technological solutions for operating theatres, critical care, and primary care, boasting over 70 years of experience in the healthcare sector. The company focuses on continuous investment in innovation, research, and development, enabling it to respond flexibly to the dynamically changing market needs and ensuring the efficiency of healthcare systems. Brandon Medical offers a comprehensive portfolio of products, including surgical lights and control panels, and is characterised by a strong focus on personal customer service and ethical values in its business practices. Brandon Medical is a respected player in the medical technology sector, and this acquisition is part of its long-term succession plan to ensure the company’s strategic growth and sustained success in a dynamic and fast-changing marketplace. “As part of a larger group we now have the opportunity to leverage a wider pool of expertise, resources, and innovation. This will allow us to accelerate innovation and enhance the value we deliver to our customers, partners, and stakeholders. Together, we are positioned to drive even greater success, fostering innovation and creating new opportunities in our global markets,” said Adrian Hall Chief Executive Officer, Brandon Medical.
RCP calls for doctors to have more ringfenced time for clinical research
Doctors should be given protected time to conduct clinical research, says the Royal College of Physicians (RCP). Findings from the 2023 census of UK consultant physicians show that over a third of doctors (36%) want to participate in research but that a lack of ringfenced time in job plans is the main thing stopping them. According to the census, only 41% of UK consultant physician respondents were involved in research, with time constraints cited as the most significant barrier to greater involvement in it. The main barrier to participating in research was time in job plans (52%), followed by facing barriers to undertaking research in their organisation (12%), being unsure how to take research proposals forward (11%), and a lack of confidence (10%). When asked about their ideal job structure, 1 in
4 respondents said they would prioritise research activity over all other Supporting Professional Activities (SPA), and akin to direct clinical care. For those who were able to participate in clinical
10
www.clinicalservicesjournal.com I December 2024
research, their top reasons for doing so were that it improves patient care, enhances clinical skills and increases job satisfaction. Given the critical benefits of research - including
improving healthcare delivery and advancing physicians’ own development - the RCP is calling for ringfenced time for research to be expanded across all specialties and consistently protected in job plans right from the start of doctors’ careers. Such a move would not only strengthen the evidence base for better patient outcomes but also help retain skilled physicians by enhancing job satisfaction. The survey also revealed the gender imbalance in research among physicians. In 2023, of the 41% (1,234 of 2,992) of UK consultant physicians reporting that they undertake any research activity, 63% (772) were male, compared to 37% (462) who were female. Findings from the 2022 UK consultant physician census showed that men were 1.6 times more likely to undertake research as a consultant physician compared to women.
Sponsored by
Rebrand provides fitting tribute
The first product rebranded by a Shropshire business has hit the sales market and it’s a very special one - named in memory of the sales director of the family-run business who died seven years ago. Telford-based global hygiene and decontamination specialist Serchem underwent the rebrand at the start of the year after welcoming a new investment team to drive the next stage of its international growth following a record-breaking year for the company. The first product released by the company
following the rebrand is PDA 51, which stands for Paul David Arnold who died at the age of 51 in 2017. Paul was the Sales Director at Serchem - a company founded by his father Clive in 1981. PDA 51 was also the first product developed by the company after Paul’s death, something he was particularly keen on and wanted to see introduced onto the market. Paul’s wife Alison, Serchem’s Commercial
director, said: “It’s fitting that the first product we’ve packed in our new branding is PDA 51, particularly when you consider just how much it meant to Paul. PDA 51 is an alkaline hospital instrument detergent concentrate designed for use in washer disinfectors, ultrasonic machines, sonic irrigators and manual cleaning. It’s an important addition to our product range and is suitable for all makes of automated washers. “Our rebrand in January was a major landmark for the company while at the same time being a particularly poignant reminder of Paul, and staff were touched to hear that our branding agency had designed our new logo complete with a hidden ‘P’ incorporated within it.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
